Clinical Trial Update: A Study to Evaluate IBI112 in the Treatment of Subjects With Moderate to Severe Plaque Psoriasis [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating IBI112 for moderate to severe plaque psoriasis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Psoriasis

Drugs mentioned

• IBI112

Snippet

Sponsor: Innovent Biologics (Suzhou) Co. Ltd. | Conditions: Psoriasis | Phase 2 | Status: COMPLETED